Stoke Therapeutics filings document regulatory disclosures for a Nasdaq-listed biotechnology company developing RNA medicines, including zorevunersen for Dravet syndrome. Recent 8-K reports cover quarterly financial results, clinical-program updates, capital resources, material agreements, lease obligations, board appointments, executive compensation, auditor changes, and Regulation FD disclosures.
The company’s definitive proxy materials describe annual meeting voting matters, director elections, board committee structure, governance practices, equity compensation, and related stockholder information. Filings also identify its common stock registered on the Nasdaq Global Select Market under STOK.
Stoke Therapeutics reported Q2 2026 results reflecting continued investment ahead of potential commercialization. Revenue for the quarter was $9.3 million, primarily from collaboration and licensing agreements, and the company recorded a net loss of $61.6 million, or $0.93 per share, driven by higher research and development and sales, general and administrative expenses.
Cash, cash equivalents and marketable securities totaled $420.0 million, based on $354.3 million at June 30, 2026 plus $65.7 million of ATM proceeds, and these funds are expected to support operations through a potential U.S. commercialization of lead Dravet syndrome candidate zorevunersen in early 2028.
Enrollment is complete for 162 patients in the global Phase 3 EMPEROR study of zorevunersen, with a pre‑NDA FDA meeting planned for the second half of 2026, rolling NDA initiation in the first quarter of 2027 and a data readout anticipated in the third quarter of 2027. The Phase 1 OSPREY trial of STK‑002 for Autosomal Dominant Optic Atrophy is progressing through dose‑escalation cohorts, with initial safety and efficacy data expected in the first half of 2027.
Stoke Therapeutics, Inc. director Seth Loring Harrison reported 16 bona fide gift transfers on July 16, 2026, moving stock options over 303,190 underlying common shares from his direct holdings to the East Pillar 2026 Irrevocable Trust. The options are fully vested, with exercise prices between $10.90 and $40.37 and expirations from 2029 to 2036. The gifts were made for no consideration and are exempt from short-swing profit liability under Rule 16b-5.
Stoke Therapeutics, Inc. reported that Chief Scientific Officer Thomas McCauley received a grant of stock options covering 225,000 shares of common stock at an exercise price of $29.91 per share, expiring on July 14, 2036. The option vests as to 1/4 of the award on July 15, 2027, and as to 1/48 of the award monthly thereafter, subject to his continued service.
Stoke Therapeutics, Inc. reports that Thomas McCauley, its Chief Scientific Officer, is an executive officer but not a director or 10% owner. This is an initial statement of insider status and, in the data provided, does not list any specific stock transactions or derivative positions.
Stoke Therapeutics Chief Medical Officer Barry Ticho reported open‑market sales of company stock. On July 1, 2026, he sold a total of 7,228 shares of Common Stock in two transactions.
The first sale covered 6,728 shares at a weighted average price of $32.615 per share, and the second sale covered 500 shares at a weighted average price of $33.2678 per share. The filing notes these trades were executed under a Rule 10b5-1 trading plan adopted on November 19, 2025, indicating they were pre‑scheduled rather than discretionary.
Issuer filed a Form 144 notice relating to proposed sales and recent 10b5-1 transactions in the issuer's common stock. The filing lists 7,228 restricted stock units dated 03/15/2026 as securities to be sold. It also records 10b5-1 sales of 1,795 shares for $54,891.10 on 06/01/2026 and 2,243 shares for $73,547.97 on 05/01/2026.
Stoke Therapeutics reported completion of enrollment of 162 patients in its pivotal Phase 3 EMPEROR study of zorevunersen for Dravet syndrome across the U.S., U.K. and Japan. This late-stage trial will measure change in major motor seizure frequency at Week 28, with full analysis over 52 weeks.
About 50 patients have already reached 28 weeks of treatment, and an additional cohort of roughly 30 patients in Europe is still enrolling, with the last patient expected in August. Stoke plans to begin a rolling U.S. New Drug Application submission in the first quarter of 2027, aiming to complete it in the second half of 2027 after an anticipated Phase 3 data readout in the third quarter of 2027.
Stoke Therapeutics, Inc. General Counsel and Corporate Secretary Jonathan Allan reported an open-market sale of Common Stock. On June 16, 2026, he sold 1,457 shares at a price of $29.95 per share. Following this transaction, he directly holds 18,086 shares of Common Stock. The sale was executed pursuant to a pre-established Rule 10b5-1 trading plan adopted on November 10, 2025, indicating the trade was made under a pre-arranged schedule rather than as a discretionary market-timing decision.
Morgan Stanley Smith Barney LLC Executive Financial Services filed a Form 144 disclosing insider sales by Jonathan Allan under a 10b5-1 plan. The filing lists dispositions of 9,293, 9,293, 4,628 and 4,267 shares on 03/20/2026, 03/20/2026, 03/18/2026 and 03/17/2026, with cash amounts shown for each trade. The filing also references Restricted Stock Units dated 03/15/2026.
Stoke Therapeutics director Arthur Tzianabos received a grant of options for 17,786 shares of common stock. The Director Stock Option has an exercise price of $29.46 per share and expires on June 2, 2036. It will vest in full on the earlier of June 3, 2027 or the company’s next annual stockholder meeting, subject to his continued service.